These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 10221288)
1. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Ostroff RB; Nelson JC J Clin Psychiatry; 1999 Apr; 60(4):256-9. PubMed ID: 10221288 [TBL] [Abstract][Full Text] [Related]
2. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. Hirose S; Ashby CR J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455 [TBL] [Abstract][Full Text] [Related]
3. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. O'Connor M; Silver H J Clin Psychopharmacol; 1998 Feb; 18(1):89-91. PubMed ID: 9472852 [No Abstract] [Full Text] [Related]
4. Risperidone and paroxetine given singly and in combination for bipolar depression. Shelton RC; Stahl SM J Clin Psychiatry; 2004 Dec; 65(12):1715-9. PubMed ID: 15641878 [TBL] [Abstract][Full Text] [Related]
5. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression]. Weimer E; Braus DF; Cavus I; Thome J Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436 [TBL] [Abstract][Full Text] [Related]
7. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. Stoll AL; Pillay SS; Diamond L; Workum SB; Cole JO J Clin Psychiatry; 1996 Feb; 57(2):72-6. PubMed ID: 8591972 [TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469 [TBL] [Abstract][Full Text] [Related]
9. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522 [TBL] [Abstract][Full Text] [Related]
10. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835 [TBL] [Abstract][Full Text] [Related]
12. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. Agid O; Lerer B J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882 [No Abstract] [Full Text] [Related]
13. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Stein MB; Kline NA; Matloff JL Am J Psychiatry; 2002 Oct; 159(10):1777-9. PubMed ID: 12359687 [TBL] [Abstract][Full Text] [Related]
14. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567 [TBL] [Abstract][Full Text] [Related]
15. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Weiss EL; Potenza MN; McDougle CJ; Epperson CN J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634 [TBL] [Abstract][Full Text] [Related]
16. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick R; Chen J; Entsuah AR; Schatzberg AF J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275 [TBL] [Abstract][Full Text] [Related]
17. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Smith WT; Londborg PD; Glaudin V; Painter JR Am J Psychiatry; 1998 Oct; 155(10):1339-45. PubMed ID: 9766764 [TBL] [Abstract][Full Text] [Related]
18. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas GI; Petersen TJ; Kinrys G; Burns AM; Worthington JJ; Alpert JE; Fava M; Nierenberg AA J Clin Psychiatry; 2005 Oct; 66(10):1326-30. PubMed ID: 16259548 [TBL] [Abstract][Full Text] [Related]
19. [Interest of the use of pindolol in the treatment of depression: review]. Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704 [TBL] [Abstract][Full Text] [Related]
20. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]